Newamsterdam Pharma CO NV Form 4 insider transactions

A recent SEC Form 4 filing reveals that James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V., has increased his indirect beneficial ownership through significant share acquisitions in late June 2025.

NewAmsterdam Pharma Co N.V.'s Chief Operating Officer, Douglas F. Kling, engaged in significant stock transactions, exercising options and selling shares under a Rule 10b5-1 trading plan.

James N. Topper, a Director and 10% Owner of NewAmsterdam Pharma Co N.V., has acquired 8,584 ordinary shares at a weighted average price of $19.4992 per share.

Michael F. Marino III, Chief Legal Officer and Corporate Secretary of NewAmsterdam Pharma Co N.V., has acquired 55,000 restricted stock units and 315,000 stock options, aligning his interests with long-term shareholder value.

NewAmsterdam Pharma Co N.V. Director Louis G. Lange converted 68 Restricted Stock Units into ordinary shares on June 1, 2025, increasing his indirect beneficial ownership to 28,186 shares.

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., executed options to acquire 100,000 ordinary shares and subsequently sold them, along with other shares, under a pre-arranged trading plan.

Juliette Berangere Audet, Chief Strategy and Business Officer of NewAmsterdam Pharma Co N.V., acquired options to purchase 30,000 ordinary shares.

Director Louis G. Lange reports changes in beneficial ownership of NewAmsterdam Pharma Co N.V. ordinary shares and Restricted Stock Units (RSUs) due to vesting.

Director Louis G. Lange reports acquisition of ordinary shares and vesting of restricted stock units in NewAmsterdam Pharma.

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., sold 99,090 and 910 ordinary shares at prices ranging from $15.70 to $16.88, and exercised options to acquire 100,000 shares at $10.

Director Adele M. Gulfo acquired shares and options in NewAmsterdam Pharma Co N.V. on April 15, 2025.

Director James N. Topper reported the acquisition of 1,135 ordinary shares of NewAmsterdam Pharma Co N.V. at a weighted average price of $22.4851.

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reports acquisition and disposal of ordinary shares and restricted stock units on March 26, 2025.

Director Louis G. Lange reports the acquisition and disposal of ordinary shares and restricted stock units in NewAmsterdam Pharma Co N.V. on March 26, 2025.

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma Co N.V., reports acquisition of ordinary shares and restricted stock units (RSUs) related to a clinical development milestone achieved under the business combination agreement.

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., reports the acquisition and disposal of ordinary shares related to the vesting of restricted stock units (RSUs).

CEO Michael Davidson reports acquisition and disposal of NewAmsterdam Pharma shares and restricted stock units (RSUs) related to a clinical development milestone achieved under the business combination agreement.

Johannes Jacob Pieter Kastelein, Chief Scientific Officer of NewAmsterdam Pharma Co N.V., reports acquisition of shares and options.

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., exercised options to acquire shares and subsequently sold a portion of those shares on March 17, 2025.

Director James N. Topper reports the acquisition of NewAmsterdam Pharma Co N.V. shares through a transaction on March 4, 2025.

Louise Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V., reports the acquisition and disposition of ordinary shares and derivative securities.

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., executed sales of ordinary shares on February 18 and 19, 2025, under a pre-arranged trading plan.

Douglas Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., reported the sale of ordinary shares on January 29th and 30th, 2025, alongside the exercise of options to acquire shares.

Mayur Ian Somaiya, CFO of NewAmsterdam Pharma Co N.V., exercised options and sold ordinary shares under a pre-arranged trading plan.

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma Co N.V., executed multiple sales of ordinary shares between January 27 and January 28, 2025, under a pre-arranged trading plan.

Director John W. Smither of NewAmsterdam Pharma Co N.V. acquired 6,960 restricted stock units and options for 32,500 ordinary shares.

Mark C. McKenna, a director at NewAmsterdam Pharma Co N.V., acquired 6,960 restricted stock units and options for 32,500 ordinary shares.

Director William Lewis of NewAmsterdam Pharma Co N.V. acquired 6,960 restricted stock units and options for 32,500 ordinary shares.

Director Hilde Johanna van der Kamp acquired 6,960 restricted stock units and options for 32,500 ordinary shares in NewAmsterdam Pharma Co N.V.

Director Louis G. Lange of NewAmsterdam Pharma Co N.V. acquired shares and options, including restricted stock units and stock options, as part of his compensation.